Commentary: Is the scare of the new botulinum serotype over? Online publication date: Thu, 04-Aug-2016
by Bal Ram Singh
The Botulinum J. (TBJ), Vol. 3, No. 1, 2015
Abstract: The highly toxic nature of botulinum neurotoxins and their placement in category A biothreat agents list under tier 1 biosecurity regulations always attract public attention about any possibility of a new form of this agent. Last time, a new type of botulinum neurotoxin (type G) was discovered was over 40 years ago, and that was not even known to cause human botulism epidemiologically. Therefore, when a novel botulinum neurotoxin was isolated from an infant botulism case in California, it became a major concern for the public health and biothreat agencies. There has been controversy among the scientists about its nomenclature. The scientific debate has been robust, and although the novel neurotoxin is now confirmed to be a hybrid of types A and F botulinum neurotoxins, the issue of calling it a new serotype (H) remains unsettled.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the The Botulinum J. (TBJ):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com